LEO-29102
- Generic Name
- LEO-29102
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.
Phase 1
Terminated
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: LEO 29102 Cream Vehicle
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 58
- Registration Number
- NCT01447758
- Locations
- 🇩🇪
Universitätshautklinik Essen, Essen, Germany
🇩🇪Clinical Trial Center North, Hamburg, Germany
🇩🇪Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 102
- Registration Number
- NCT01423656
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
LEO 29102 Cream in the Treatment of Atopic Dermatitis
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 183
- Registration Number
- NCT01037881
- Locations
- 🇨🇦
Windsor Clinical Research Inc., Windsor, Ontario, Canada
🇫🇮Helsinki University Central Hospital, Helsinki, Finland
🇩🇪Klinik und Poliklinik für Dermatologie, Universität Bonn, Bonn, Germany
LEO 29102 Single and Multiple Dose Study by Dermal Application
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 64
- Registration Number
- NCT00891709
- Locations
- 🇬🇧
LCG Bioscience, Bourn, Cambridgeshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath